Syngene International Limited has officially announced leadership changes as Jonathan Hunt steps down from his role as MD & CEO as well as from the Board of Directors. This transition is effective immediately, with Peter Bains taking over as the CEO Designate of Syngene.
Kiran Mazumdar-Shaw, Non-Executive Chairperson of Syngene International, expressed her gratitude for Hunt’s contributions, stating, “After almost 10 years with Syngene, Jonathan Hunt’s leadership has driven significant growth and value enhancement for the company since 2016. We wish him success in his future endeavors.”
Peter Bains, who previously served as CEO of Syngene from 2010 to 2016, played a pivotal role in strengthening the company’s foundation and taking it public in 2015. His extensive experience in the biotech and pharmaceutical sectors, coupled with his familiarity with the company, is expected to ensure a seamless transition and sustained growth for Syngene.
About Syngene International: Syngene International Ltd. is a leading integrated research, development, and manufacturing services company, catering to sectors like pharmaceuticals, biotechnology, and specialty chemicals. With over 5,600 scientists and 2.2 million sq. ft of specialized facilities, Syngene collaborates with prominent companies such as BMS, GSK, and Zoetis to deliver innovation and robust manufacturing solutions globally.
